THE INSTITUTE’S RESEARCH PROGRAMS
Covid-19 & trisomY 21
Studying the characteristics of patients with T21 monitored by the Jérôme Lejeune Institute who have been infected with SARS-CoV-2
This research project aims to study the characteristics – especially clinical – of patients with T21 monitored by the Jérôme Lejeune Institute and who have been infected with SARS-CoV-2
People with trisomy 21 have a higher risk of airway infections, especially infections caused by flu and respiratory syncytial virus.1 COVID-19 presents a wide range of clinical signs, from slight flu-like symptoms to severe interstitial pneumonia.2
The international investigation carried out by the Trisomy 21 Research Society (T21RS) – in which the Jérôme Lejeune Institute is participating – shows that people with trisomy 21 have a higher risk of a serious form of COVID-19 beyond the age of 40 years old and/or if certain comorbidities are present (especially diabetes, obesity, Alzheimer’s disease, etc.). The response of people with trisomy 21 to this infection is not yet well understood, especially from a clinical perspective.
1. Respiratory syncytial virus: a virus causing usually mild seasonal community-acquired respiratory affections.
2. Interstitial pneumonia: a respiratory affection linked to disease of the lung interstitium, i.e. the tissue between the alveoli.
The objectives of the T21 and COVID+ study are:
- To describe the characteristicsof patients with T21 monitored by the Jérôme Lejeune Institute who have had a diagnosed SARS-CoV-2 infection
- To assess the profileof patients who contracted a severe or lethal form, compared to the profile of people with other forms (moderate or asymptomatic).
For the purposes of the study, data from 155 people of all ages with trisomy 21 monitored by the Jérôme Lejeune Institute, and who had a consultation between 1 March 2020 and 30 June 2021 during which SARS-CoV-2 was reported, will be analyzed.